iwCLL 2023 | Resistance to non-covalent BTKi’s
Varsha Gandhi
• 7 Oct 2023
In this video, Varsha Gandhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the investigation, undertaken at the MD Anderson Cancer Centre, into resistance to non-covalent BTK inhibitors (BTKi’s), namely pirtobrutinib, in patients with chronic lymphocytic leukemia (CLL). Dr Gandhi highlights the driver mutations commonly observed in these patients before and during treatment. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
